The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations

Jacek Jassem; Wojciech Biernat; Maciej Bryl; Joanna Chorostowska-Wynimko; Rafał Dziadziuszko; Paweł Krawczyk; Radzisław Kordek; Dariusz M. Kowalski; Maciej Krzakowski; Włodzimierz Olszewski; Tadeusz Orłowski; Rodryg Ramlau; Witold Rzyman

Oncology in Clinical Practice
Vol 10, No 1 (2014) The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations

Vol 10, No 1 (2014)

Guidelines / Expert consensus

Published online: 2014-03-06

View PDF (Polish) Download PDF file

Page views 711

Article views/downloads 1804

Get Citation

Connect on Social Media

The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations

Jacek Jassem, Wojciech Biernat, Maciej Bryl, Joanna Chorostowska-Wynimko, Rafał Dziadziuszko, Paweł Krawczyk, Radzisław Kordek, Dariusz M. Kowalski, Maciej Krzakowski, Włodzimierz Olszewski, Tadeusz Orłowski, Rodryg Ramlau, Witold Rzyman

Onkol. Prak. Klin 2014;10(1):1-15.

Abstract

Lung cancer is the leading cause of cancer related death in Poland. About 85% of all lung cancer constitutes non-small cancer (NSCLC), in which the role of cytotoxic and molecularly targeted drugs is increasing. This article presents the current evidence-based recommendations for the use of these methods in clinical practice in NSCLC and malignant pleural mesothelioma.

Keywords: non-small-lung cancer — treatmentpleural mesothelioma — treatment

Article available in PDF format

View PDF (Polish) Download PDF file

Oncology in Clinical Practice

About Via Medica Advertising

Bookstore (Ikamed) TVMed

News